

IFW 1624

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 19711	
In Re Application Of: Elfi Biedermann et al.						
Application No. 09/596,086	Filing Date June 16, 2000	Examiner Brenda Libby Coleman	Customer No. 23389	Group Art Unit 1624	Confirmation No. 3172	
Title: <b>ALKYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS</b>						
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p><b>OR</b></p> <p><input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>						


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

19711

In Re Application of: Elfi Biedermann et al.



Application No.

09/596,086

Filing Date

June 16, 2000

Examiner

Brenda Libby Coleman

Customer No.

23389

Group Art Unit

1624

Confirmation No.

3172

Title: **ALKYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES  
USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 11, 2006

(Date)

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Mark J. Cohen

Registration No.: 32,211

Scully, Scott, Murphy &amp; Presser, P.C.


400 Garden City Plaza, Suite 300

Garden City, New York 11530

(516) 742-4343

Dated: November 11, 2006

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Elfi Biedermann et al. **Examiner:** Brenda Libby Coleman  
**Serial No:** 09/596,086 **Art Unit:** 1624  
**Filed:** June 16, 2000 **Docket:** 19711  
**For:** **ALKYL-SUBSTITUTED  
PYRIDYLALKANE,  
ALKENE AND ALKINE  
CARBOXAMIDES  
USEFUL AS CYTOSTATIC AND  
IMMUNOSUPPRESSIVE AGENTS** **Dated:** November 13, 2006

**Confirmation No: 3172**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. M. Eder, P. Gedigk, (Ed.), "Allgemeine Pathologie und Pathologische Anatomie", Springer Verlag, Berlin, 33<sup>rd</sup> Ed., 1990, pps. 208-213 and translation of relevant passages thereof;
2. Chemical Abstracts, Vol. 124, No. 13, 1996, p. 1004, 1730915r;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 13, 2006.

Dated: November 13, 2006

  
Mark J. Cohen

11/16/2006 SSESHE1 00000008 09596086

01 FC:1806

180.00 DP


3. Chemical Abstracts, Vol. 115, 1991, p. 48, 150041w; and
4. Chemical Abstracts, Vol. 114, 1991, p. 714, 101646t.

Applicants are submitting copies of the above-cited references. It is to be noted that the first item is in the German language. Applicants are also submitting herewith an English translation of the relevant passages thereof.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), applicants are submitting the fee set forth in 37 C.F.R. §1.17(d).

Respectfully submitted,



Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza – Suite 300  
Garden City, New York 11530  
(516) 742-4343

MJC:ahs

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	<b>Docket Number (Optional)</b> <div style="text-align: center; font-weight: bold;">19711</div>	<b>Application Number</b> <div style="text-align: center; font-weight: bold;">09/596,</div>
	<b>Applicant(s)</b> <div style="text-align: center; font-weight: bold;">Elfi Biedermann et al.</div>	
	<b>Filing Date</b> <div style="text-align: center; font-weight: bold;">June 16, 2000</div>	<b>Group Art Unit</b> <div style="text-align: center; font-weight: bold;">1624</div>

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		M. Eder, P. Gedigk, (Ed.), "Allgemeine Pathologie und Pathologische Anatomie", Springer Verlag, Berlin, 33rd Ed., 1990, pps. 208-213 and translation of relevant passages thereof Chemical Abstracts, Vol. 124, No. 13, 1996, p. 1004, 1730915r
		Chemical Abstracts, Vol. 115, 1991, p. 48, 150041w Chemical Abstracts, Vol. 114, 1991, p. 714, 101646t

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.